Chimeric TNT-3 antibody/murine interferon-γ fusion protein for the immunotherapy of solid malignancies

Hybridoma and Hybridomics

Volumn 22, Issue 4, 2003, Pages 197-207

  Mizokami, Myra M ^a   Hu, Peisheng ^a   Khawli, Leslie A ^a   Li, Jiali ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; HYBRID PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS THERAPY 3 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; GENE AMPLIFICATION; GENE TARGETING; IMMUNOTHERAPY; LUNG CARCINOMA; LUNG METASTASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PURIFICATION; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS;

ANIMALIA; MURINAE;

EID: 0041335450     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685903322328929     Document Type: Article

References (52)

1. De Maeyer E, and De Maeyer-Guignard J: Interferons. In: The Cytokine Handbook, Vol. 1. Thomson A (Ed.). Academic Press, San Diego, 1994, pp. 265-288.
2. Talmadge JE, Tribble HR, Pennington RW, Phillips H, and Wiltrout RH: Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 1987;47:2563-2570.
3. Sato N, Nariuchi H, Tsuruoka N, Nishihara T, Beitz J, Calabresi P, and Frackelton AJ: Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 1990;95:85S-89S.
4. Ibe S, Qin Z, Schuler T, Preiss S, and Blankenstein T: Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194:1549-1559.
5. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-686.
6. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, and Gately MK: Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 1995;17:71-77.
7. Voest E, Kenyon B, O'Reilly M, Truitt G, D'Amato R, and Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995;87:581-586.
8. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A, et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1265-1271.
9. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, and Gutterman JU: Pharmacokinetics, single-dose tolerance, and biological activity of recombinant γ-interferon in cancer patients. Cancer Res 1985;45:2866-2872.
10. Kurzrock R, Quesada JR, Rosenblum MG, Sherwin SA, and Gutterman JU: Phase I study of iv administrated recombinant gamma interferon in cancer patients. Cancer Treat Rep 1986;70:1357-1364.
11. Dianzani F, Salter L, Fleischmann WR Jr, and Zucca M: Immune interferon activates cells more slowly than does virus-induced interferon. Proc Soc Exp Biol Med 1978;159:94-97.
12. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, and Gilboa E: Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-7825.
13. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, and Blankenstein T: Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or interferon-γ. Proc Natl Acad Sci USA 1993;90:2774-2778.
14. Yanagihara K, Seyama T, and Watanabe Y: Antitumor potential of interferon-γ: retroviral expression of mouse interferon-γ cDNA in two kinds of highly metastatic mouse tumor lines reduces their tumorigenicity. Nat Immun 1994;13:102-112.
15. Sadanaga N, Nagoshi M, Lederer J, Joo H-G, Eberlein TJ, and Goedegebuure PS: Local secretion of IFN-γ induces an antitumor response: Comparison between T cells plus IL-2 and IFN-γ transfected tumor cells. J Immunother 1999;22:315-323.
16. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, and Yang N-S: In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 1995;92:2889-2893.
17. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, and Bromberg JS: Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum Gene Ther 1997;8:2019-2029.
18. Ghazizadeh S, Carroll JM, and Taichman LB: Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol 1997;71:9163-9169.
19. Chen F-M, Taylor CR, and Epstein AL: Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131-I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578-4585.
20. Epstein AL, Khawli LA, Hornick JL, and Taylor CR: Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin-2. Cancer Res 1995;55:2673-2680.
21. Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, and Epstein AL: A chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13:255-268.
22. Lundberg B, Griffiths G, and Hansen H: Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions. J Pharm Pharmacol 1999;51:1099-1105.
23. Rosenblum MG, Marks JW, and Cheung LH: Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Cancer Chemother Pharmacol 1999;44:343-348.
24. Chen F-M, Epstein AL, Li Z, and Taylor CR: A comparative autoradiographic study demonstrating differential intra-tumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. J Nucl Med 1990;31:1059-1066.
25. Chen F-M, Hansen EB, Taylor CR, and Epstein AL: Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J Natl Cancer Inst 1991;83:200-204.
26. Epstein AL, Chen F-M, and Taylor CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988;48:5842-5848.
27. Epstein AL, Chen D, Ansari A, Najafi A, Siegel M, Lee K, Hu E, Rosen P, Watkins K, Stain S, Weaver F, and Taylor CR: Radioimmunodetection of necrotic lesions in human tumors using 1-131-labeled TNT-1 F(ab′)2 monoclonal antibody. Antibody Immunoconjugates Radiopharm 1991;4:151-161.
28. Sharifi J, Khawli LA, Hu P, King S, and Epstein AL: Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybridoma Hybridomics 2001;20:305-312.
29. Khawli LA, Mizokami MM, Sharafi J, Hu P, and Epstein AL: Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 antibodies after chemical modification with biotin. Cancer Biother Radiopharm 2002;17:359-370.
30. Sharifi J, Khawli LA, Li J, Hu P, and Epstein AL: Generation of human interferon gamma and tumor necrosis factor-alpha chimeric TNT-3 fusion proteins. Hybridoma Hybridomics 2002;21:421-432.
31. Epstein M, Achong B, Barr Y, Zajac B, Henle G, and Henle W: Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966;37:547-559.
32. Kappler J, Skidmore B, White J, and Marrack P: Antigen-inducible, H-2 restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med 1981;153:1198-1214.
33. Ralph P, and Nakoinz I: Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. J Immunol 1977;119:950-954.
34. Murphy GP, and Hrushesky WJ: A murine renal cell carcinoma. J Natl Cancer Inst 1973;50:1013-1025.
35. Ralph P, Moore M, and Nilsson K: Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med 1976;143:1528-1533.
36. Marks TA, Woodman RJ, Geran RI, Billups LH, and Madison RM: Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents. Cancer Treat Rep 1977;61:1459-1470.
37. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, and Epstein AL: Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res 1999;5:51-60.
38. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, and Epstein AL: A chimeric Lym-1/interleukin-2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 1996;56:4998-5004.
39. Hu P, Glasky MS, Yun A, Alauddin MM, Hornick JL, Khawli LA, and Epstein AL: A human-mouse chimeric Lyre-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibodies 1995;6:57-67.
40. Frankel ME, and Gerhard W: The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: an analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol 1979;16:101-106.
41. Schreiber RD: Measurement of mouse and human interferon-γ. In: Current Protocols in Immunology. Vol. 1. Colligan JE (Ed.). Wiley, New York, 1994, pp. 6.8.1-6.8.8.
42. Kim Y-M, and Son K: A nitric oxide production bioassay for interferon-γ. J Immunol Methods 1996;198:203-209.
43. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, and Morrison SL: the use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994;73:794-799.
44. Hornick JL, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, Mizokami MM, and Epstein AL: Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med 2000;41:355-362.
45. Wexler H: Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966;36:641-645.
46. Yao L, Sgadari C, Furuke K, Bloom E, Teruya-Feldstein J, and Tosato G: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-1621.
47. Qi Y, Chen Y, and Xiang J: Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-γ elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res 1996;16:771-776.
48. Qi Y, Moyana T, Chen Y, and Xiang J: Characterization of antitumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-γ. Hum Antibodies 1996;7:21-26.
49. Xiang J, Qi Y, Luo X, and Liu E: Recombinant bifunctional molecule FV/IFN-γ possesses the anti-tumor FV as well as the gamma interferon activities. Cancer Biother 1993;8:327-337.
50. Xiang J, Qi Y, Cook D, and Moyana T: Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Hum Antibodies 1996;7:2-10.
51. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, and Epstein AL: Chimeric CLL-1 antibody fusion protein containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 1997;89:4437-4447.
52. Li J, Hu P, Khawli LA, and Epstein AL: LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J Immunother 2003;26:320-331.